Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics (GB:STX)
:STX
STX Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.50p - 5.87p
Previous CloseN/A
Volume699.61K
Average Volume (3M)851.09K
Market Cap
£33.33M
Enterprise Value211.45M
Total Cash (Recent Filing)£5.61M
Total Debt (Recent Filing)£21.06M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Sep 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,041,690,400
10 Day Avg. Volume755,233
30 Day Avg. Volume851,094
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.03
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2.50Price Target Upside-21.88% Downside
Rating ConsensusHold
Number of Analyst Covering1
Shield Therapeutics News
PremiumCompany Announcements
Shield Therapeutics Secures Shareholder Support at 2025 AGM
PremiumCompany Announcements
Shield Therapeutics Partners with VITAL-NET for ACCRUFeR® Launch in Japan
PremiumCompany Announcements
Shield Therapeutics Reports Q1 2025 Revenue Growth and Strategic Progress
Bulls Say, Bears Say
Bulls Say
Financial Position$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.
Revenue GrowthThe significant increase in NSP to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.
Sales PerformanceShield's 2024 trading update sees the company expect to deliver $32.2m of revenues for 2024, driven primarily by US Accrufer sales which grew 153%.
Bears Say
Cashflow ConcernsThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.
Growth ChallengesAccrufer growth needs to continue to accelerate to meet its cashflow breakeven target of 2025YE, and there continues to be little room for error.
Prescription VolumeThe increase in NSP offsets a 6% decrease in prescription volumes QoQ, a significant slowdown vs Q2 and Q3 which delivered more than 20% prescription growth.
Options Prices
Currently, No data available
---
Ownership Overview
0.06% Insiders
―
Mutual Funds
― Other Institutional Investors
99.94% Public Companies and
Individual Investors
STX FAQ
What was Shield Therapeutics’s price range in the past 12 months?
Shield Therapeutics lowest share price was 1.50p and its highest was 5.87p in the past 12 months.
What is Shield Therapeutics’s market cap?
Shield Therapeutics’s market cap is £33.33M.
When is Shield Therapeutics’s upcoming earnings report date?
Shield Therapeutics’s upcoming earnings report date is Sep 04, 2025 which is in 52 days.
How were Shield Therapeutics’s earnings last quarter?
Shield Therapeutics released its earnings results on Apr 24, 2025. The company reported -0.011p earnings per share for the quarter, beating the consensus estimate of -0.013p by 0.002p.
Is Shield Therapeutics overvalued?
According to Wall Street analysts Shield Therapeutics’s price is currently Overvalued.
Does Shield Therapeutics pay dividends?
Shield Therapeutics does not currently pay dividends.
What is Shield Therapeutics’s EPS estimate?
Shield Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics have?
Shield Therapeutics has 1,041,690,400 shares outstanding.
What happened to Shield Therapeutics’s price movement after its last earnings report?
Shield Therapeutics reported an EPS of -0.011p in its last earnings report, beating expectations of -0.013p. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of Shield Therapeutics?
Currently, no hedge funds are holding shares in GB:STX
Shield Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£2.50 (-21.88% Downside)
£2.50 (-21.88% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
93.93%
12-Months-Change
Fundamentals
Return on Equity
-396.71%
Trailing 12-Months
Asset Growth
19.90%
Trailing 12-Months
Company Description
Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
STX Stock 12 Month Forecast
Average Price Target
2.50p
▼(-21.88%Downside)
Technical Analysis
Allergy Therapeutics
―
Alliance Pharma
―
Animalcare
―
Hikma Pharmaceuticals
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―